MedTrace Logo

Receptor Occupancy of LB-102 Using Positron Emission Tomography (PET) in Healthy Volunteers

NCT04588129 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2022-05-04

No results posted yet for this study

Summary

This is an open label study in 4 cohort of 4 healthy volunteers each designed to evaluate the dopamine receptor occupancy of LB-102 at various doses and timepoints.

Conditions

Interventions

DRUG

LB-102

(N-Methyl amisulpride)

Sponsors & Collaborators

  • Washington University School of Medicine

    collaborator OTHER

  • LB Pharmaceuticals Inc.

    lead INDUSTRY

Principal Investigators

  • Dean Wong, PhD · Washington University School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-01-05
Primary Completion
2021-09-17
Completion
2021-11-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04588129 on ClinicalTrials.gov